BridgeBio gears up for FDA review of acoramidis following Phase III results
BridgeBio submitted the NDA with US FDA for the TTR stabiliser in December 2023 and plans to engage with other regulatory bodies this year.
BridgeBio submitted the NDA with US FDA for the TTR stabiliser in December 2023 and plans to engage with other regulatory bodies this year.
What's Your Reaction?
